Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics Inc (LRMR) - Total Assets
Latest total assets as of September 2025: $187.35 Million USD
Based on the latest financial reports, Larimar Therapeutics Inc (LRMR) holds total assets worth $187.35 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Larimar Therapeutics Inc - Total Assets Trend (2012–2024)
This chart illustrates how Larimar Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Larimar Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Larimar Therapeutics Inc's total assets of $187.35 Million consist of 97.5% current assets and 2.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.6% |
| Accounts Receivable | $1.05 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Larimar Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Larimar Therapeutics Inc's current assets represent 97.5% of total assets in 2024, an increase from 94.0% in 2012.
- Cash Position: Cash and equivalents constituted 16.6% of total assets in 2024, down from 90.4% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Larimar Therapeutics Inc Competitors by Total Assets
Key competitors of Larimar Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Larimar Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Larimar Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Larimar Therapeutics Inc is currently not profitable relative to its asset base.
Larimar Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.06 | 13.10 | 10.89 |
| Quick Ratio | 4.06 | 13.15 | 10.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $138.11 Million | $ 196.97 Million | $ 88.96 Million |
Larimar Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Larimar Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.25 |
| Latest Market Cap to Assets Ratio | 1.12 |
| Asset Growth Rate (YoY) | 108.7% |
| Total Assets | $200.22 Million |
| Market Capitalization | $224.89 Million USD |
Valuation Analysis
Above Book Valuation: The market values Larimar Therapeutics Inc's assets above their book value (1.12 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Larimar Therapeutics Inc's assets grew by 108.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Larimar Therapeutics Inc (2012–2024)
The table below shows the annual total assets of Larimar Therapeutics Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $200.22 Million | +108.71% |
| 2023-12-31 | $95.94 Million | -24.11% |
| 2022-12-31 | $126.41 Million | +60.68% |
| 2021-12-31 | $78.67 Million | -24.85% |
| 2020-12-31 | $104.69 Million | +1912.81% |
| 2019-12-31 | $5.20 Million | -95.73% |
| 2018-12-31 | $121.76 Million | +15.40% |
| 2017-12-31 | $105.51 Million | -19.84% |
| 2016-12-31 | $131.62 Million | -30.40% |
| 2015-12-31 | $189.11 Million | +60.92% |
| 2014-12-31 | $117.52 Million | +208.14% |
| 2013-12-31 | $38.14 Million | +247.15% |
| 2012-12-31 | $10.99 Million | -- |